A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - ...

New research reveals these medications impact everything from heart health to restaurant menus.

This is read by an automated voice. Please report any issues or inconsistencies here. Ozempic, Zepbound, and Wegovy are now household names. And as these GLP-1 medications have exploded in popularity, ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and Mounjaro) had substantially lower five-year death rates than those not using ...

Share on Pinterest The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

Wegovy is currently not listed on the PBS and not subsidied by the Australian government.

The World Health Organization (WHO) released its first-ever guideline on using GLP-1 medications to treat obesity. The disease now affects more than 1 billion people worldwide and is tied to 3.7 ...

KFF Health News' editor-at-large for public health recently took to the airwaves to discuss topical stories. Here’s a ...

Questions surround their effects on brain health, pregnancy or long-term use. MIT Technology Review Explains: Let our writers untangle the complex, messy world of technology to help you understand ...

Type 2 diabetes patients prescribed GLP-1 receptor agonists were more likely to develop chronic cough versus those prescribed other medications. Increased cough risk persisted when patients with a ...